Magnitude of clinical responses with izokibep in psoriatic arthritis continues to improve

Privately-held US clinical-stage immunology specialist Acelyrin has announced long-term 46-week data from a global Phase II trial of izokibep in psoriatic arthritis (PsA).

Izokibep is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody.

Just last month, Acelyrin announced data from the open label Part A of a Phase IIb/III trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) that demonstrated treatment with its lead candidate izokibep resulted high orders (HiSCR75 and above) of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants, claiming these results are better than any seen before.